20+ Million Readerbase
Indexed In
  • Open J Gate
  • Genamics JournalSeek
  • ResearchBible
  • RefSeek
  • Directory of Research Journal Indexing (DRJI)
  • Hamdard University
  • OCLC- WorldCat
  • Scholarsteer
  • Publons
  • MIAR
  • Euro Pub
  • Google Scholar
Share This Page
Journal Flyer
Flyer image

Giuseppe Lazzarino


Prof. Giuseppe Lazzarino has received his Degree in Biological Sciences at the State University of Rome "La Sapienza", Rome, Italy in 1979. In 1980 he joined an Italian pharmaceutical company, becoming head of the Biochemistry and Pharmacology Research Laboratory. In 1986 he became Researcher in Biochemistry at the University of Rome "Tor Vergata", Rome, Italy. Since 1994 he is Full Professor of Biochemistry at the School of Biology of the University of Catania, Catania, Italy. During his collaborations with different groups he spent periods at the University of Oulu, Finland (Prof. Hassinen and Prof. Nuutinen), the Webb-Waring Institute for Biomedical Research, Denver, Colorado, USA (Prof. J.M. McCord), the University of Texas, Austin, USA (Prof. J.W. Starnes) and the University of Missouri, Columbia, USA (Prof. M.J. Rovetto and Prof C.H. Hardin) doing research and giving seminars and lectures. Since the end of 2010 he established a spin-off company aimed to perform metabolic screenings of biological fluids for prenatal and postnatal diagnosis of IEM, as well as to evidence biochemical markers of clinical interests. He is an author of more than 90 papers (both original articles and reviews) in the field of biochemistry and, mostly, of translational medicine (neurotraumatology, neurology, cardiology). He holds 4 patents.

Research Interest

Biochemistry, clinical biochemistry and translational medicine are the main areas of interest in prof. Giuseppe Lazzarino laboratory. In particular, he has interested in studying: 1) biochemical and metabolic changes in traumatic brain injury (both in rats and human beings); 2) energy metabolism and free radical damage in animals and human beings; 3) biochemical markers of clinical relevance in different pathological states (neurodegeneration, myocardial ischemia, etc.); 4) biochemical and molecular evaluation of IEM (inborn errors of metabolism ); 5) metabolic screenings for the prenatal diagnosis of IEM.